Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements for Subjects Treated With Eslicarbazeine Acetate (ESL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02491073
Recruitment Status : Completed
First Posted : July 7, 2015
Results First Posted : February 5, 2018
Last Update Posted : February 7, 2018
Sponsor:
Information provided by (Responsible Party):
Sunovion

Brief Summary:
The purpose of this research study is to determine if the blood tests used to measure free thyroid hormone levels are affected by a drug called eslicarbazepine acetate. To determine if eslicarbazepine acetate interferes with these blood tests, blood samples will be analysed so that researchers can compare different types of lab tests that measure these thyroid hormones. Half of the people who participate in this study will already be taking eslicarbazepine acetate either as a study drug or as a prescription (Part 1) and the other half will be people who do not take eslicarbazepine acetate (Part 2).

Condition or disease Intervention/treatment
Epilepsy Other: blood draw

Detailed Description:

Part 1 of the study will enroll a minimum of 30 male and female subjects who have received at least 1200 mg once daily (QD) ESL over a minimum 6-week period (ESL-exposed subjects). Subjects, who meet study eligibility requirements and provide written consent, will provide blood samples for measurement of thyroid hormones, thyroxine binding globulins (TBG), serum pregnancy (female subjects of childbearing potential 1only), thyroid peroxidase (TPO) antibodies, and ESL metabolites (eslicarbazepine and (R)-licarbazepine).

Optional blood samples will be requested from subjects in Part 1 who provide genetic consent and are eligible to participate (as controls) in a separate rash registry protocol. These samples will be tested for HLA typing, genetic ancestry, and viral titers (including human herpes virus [HHV]-6, HHV-7, and Epstein-Barr virus [EBV]).

ESL metabolites will be determined by a validated liquid chromatography- tandem mass spectrometry (LC-MS/MS) assay. Levels of FT4 and FT3 in ESL-exposed serum will be assayed using the automated kit assay (Roche Cobas ECLIA kits FT4 II and FT3 III) and Equilibrium Dialysis (ED) method. FT4 and FT3 results measured by both methods will be compared to evaluate potential assay differences. Serum TSH, TT4, TT3, and TBG in ESL treated subject samples will also be measured using automated kit assays.

Part 2 of the study will enroll a minimum of 30 age (± 5 y) and gender-matched non-ESL exposed volunteers. Subjects, who meet study eligibility requirements and provide written consent, will provide a blood sample for measurement of thyroid hormones, TBG, serum pregnancy (female subjects of childbearing potential only), and TPO antibodies. Serum samples obtained from non-ESL exposed subjects will be split into 4 aliquots, one aliquot will be used as the control blank (unspiked) and the rest spiked with 3 levels (high, low, and a concentration representative of therapeutic levels also called middle) of eslicarbazepine (range approximately 5 to 18 μg/mL) and (R)-licarbazepine (range approximately 0.5 to 1.8 μg/mL). The low concentration for spiking the non-ESL exposed samples will be approximately 1 standard deviation (SD) below Cavg associated with the 800 mg dose in chronic use in the epilepsy population and the high concentration for spiking will be approximately 1 SD above Cavg associated with the 1200 mg dose.

After sample is spiked with eslicarbazepine and (R)-licarbazepine, serum FT4 and FT3 will be measured by the automated kit assay method, as well as ED method. FT4 and FT3 measured in non-spiked and spiked volunteer samples will be compared to detect potential in vitro artifacts. Serum TSH, TT4, TT3, and TBG in non-spiked and spiked volunteer samples will also be measured using automated kit assays.

Layout table for study information
Study Type : Observational
Actual Enrollment : 71 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: Ex-vivo Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements Using Equilibrium Dialysis (ED) and Automated Kit Assay for Subjects Treated With Eslicarbazeine Acetate
Study Start Date : September 2015
Actual Primary Completion Date : March 2016
Actual Study Completion Date : March 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Hormones

Group/Cohort Intervention/treatment
Eslicarbazepine acetate treated Other: blood draw
Investigate the possibility of assay artifacts impacting the measurement of thyroid hormones, in particular FT4 and FT3, in ESL treated subjects compared to non-ESL-treated subjects.

Non-Eslicarbazepine acetate treated Other: blood draw
Investigate the possibility of assay artifacts impacting the measurement of thyroid hormones, in particular FT4 and FT3, in ESL treated subjects compared to non-ESL-treated subjects.




Primary Outcome Measures :
  1. Comparison of Concentrations of Free Thyroid Hormones (FT4 and FT3) as Measured by ED and Automated Kit Assay Method in ESL-exposed Subjects [ Time Frame: 1 day ]
  2. Comparison of Concentrations of Free Thyroid Hormones (FT4 and FT3) as Measured by Automated Kit Assay in Non-ESL Exposed Subjects, With and Without the in Vitro Addition of Eslicarbazepine and (R)-Licarbazepine. [ Time Frame: 1 day ]

Secondary Outcome Measures :
  1. Comparison of Concentrations of TT4, and TT3 as Measured in Non-ESL-exposed Subject Samples, With or Without the in Vitro Addition of Eslicarbazepine and (R)-Licarbazepine. [ Time Frame: 1 day ]
  2. Comparison of Concentrations of Free Thyroid Hormones (FT4 and FT3) in Spiked and Unspiked Volunteer Samples Using ED and Automated Kit Assay. [ Time Frame: 1 day ]
  3. Comparison of Concentrations of TSH,as Measured in Non-ESL-exposed Subject Samples, With or Without the in Vitro Addition of Eslicarbazepine and (R)-Licarbazepine. [ Time Frame: 1 day ]

Biospecimen Retention:   Samples With DNA
blood


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Males and Females greater than or equal to 18 years of age, either exposed to drug or not exposed to drug
Criteria

Inclusion Criteria:

  • ESL-exposed Subjects

    1. Subject must give written informed consent and privacy authorization prior to participation in the study.
    2. Male or female patient (≥ 18 years of age) who has received at least 1200 mg QD ESL for at least 6 weeks and has not experienced any rash or other allergic reaction at the time of blood draw.
  • Non-ESL-exposed Subjects

    1. Subject must give written informed consent and privacy authorization prior to participation in the study.
    2. Male or female healthy normal volunteer (≥ 18 years of age).

Exclusion Criteria:

  • Both ESL-exposed and non-ESL exposed subjects

    1. Subject who does not tolerate venipuncture or Has poor venous access that would cause difficulty for collecting blood samples.
    2. Subject with a history of thyroid disease or clinical condition (eg, renal insufficiency, Sjogren's syndrome, lupus, rheumatoid arthritis, pernicious anemia etc.) that in the opinion of the Investigator may effect levels of thyroid hormones, TBG, and/or TPO antibodies.
    3. Female subject who is pregnant.
    4. Female subject with a positive urine pregnancy test at screening.
    5. Subject who received any excluded medication for at least 30 days prior to blood draw.
    6. Subject has experienced significant blood loss and/or donated blood within last 60 days of blood draw.
    7. Subject intends to donate blood or undergo elective surgery within next 30 days following blood draw.
    8. Subject has donated plasma within last 72 hours of blood draw or intends to donate plasma during study participation.
    9. Subject is, in the opinion of the Investigator, unsuitable in any other way to participate in the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02491073


Locations
Layout table for location information
United States, Arizona
The More foundation/The Core Institute
Sun City, Arizona, United States, 85351
United States, Idaho
Consultans in Epilepsy & Neurology, PLLC
Boise, Idaho, United States, 83702
United States, Kentucky
Bluegrass Epilepsy Research
Lexington, Kentucky, United States, 40504
United States, Maryland
Mid-Atlantic Epilepsy Center
Bethesda, Maryland, United States, 20817
United States, Minnesota
Minneapolis Clinic of Neurology
Golden Valley, Minnesota, United States, 55422
United States, New York
CliniLabs
New York, New York, United States, 10019
United States, Texas
NeurologicalClinic of Texas, P.A.
Dallas, Texas, United States, 75251
Sponsors and Collaborators
Sunovion
Investigators
Layout table for investigator information
Study Chair: CNS Medical Director Sunovion
Layout table for additonal information
Responsible Party: Sunovion
ClinicalTrials.gov Identifier: NCT02491073    
Other Study ID Numbers: SEP093-451
First Posted: July 7, 2015    Key Record Dates
Results First Posted: February 5, 2018
Last Update Posted: February 7, 2018
Last Verified: February 2018
Additional relevant MeSH terms:
Layout table for MeSH terms
Epilepsy
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases